Ocrelizumab biosimilar (CinnaGen)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOcrelizumab biosimilar (CinnaGen)

Drug Alias NameN/A

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesCinnagen

China Registration ClassN/A

Active CompaniesCinnagen

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis

Inactive IndicationsN/A

ATC CodeL04AG08